Standard Chemical & Pharmaceutical Group continues to lead the industry in profitability, with its three listed entities—Standard Chemical & Pharmaceutical, Syngen Biotech, and Syn-Tech Chem. & Pharm—all earning over half a share capital last year.

• Standard Chemical & Pharmaceutical: Reported a record EPS of $5.19. For the first time in 15 years, the board approved a stock dividend ($1) alongside a cash dividend ($2), signaling a strategic move to retain capital for aggressive expansion. The company’s new high-density automated warehouse will go live in 2026, with a new 200-ping production line extension slated for 2028.
• Syngen Biotech: Achieved an EPS of $10.20, returning to double-digit profitability. Chairman Chen Wei-ren noted that despite the post-pandemic adjustment in supplements, the company is pivoting toward a new business model involving strategic alliances for raw material development. A new medicinal capsule facility is expected to contribute significantly in H2 2026.
• Syn-Tech Chem. & Pharm: Reported a stable EPS of $5.87. Following a recovery from a past fire, the company’s nine plants are operating at 70% capacity. Notably, its market share in Japan has surged from 20% to over 30%, focusing on high-demand CNS and GI APIs.

Resource: 生達集團 蟬聯製藥獲利王